509 related articles for article (PubMed ID: 20073038)
1. Emerging roles of deubiquitinases in cancer-associated pathways.
Sacco JJ; Coulson JM; Clague MJ; Urbé S
IUBMB Life; 2010 Feb; 62(2):140-57. PubMed ID: 20073038
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets.
Shi D; Grossman SR
Cancer Biol Ther; 2010 Oct; 10(8):737-47. PubMed ID: 20930542
[TBL] [Abstract][Full Text] [Related]
3. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer.
Satija YK; Bhardwaj A; Das S
Int J Cancer; 2013 Dec; 133(12):2759-68. PubMed ID: 23436247
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinases in the regulation of NF-κB signaling.
Harhaj EW; Dixit VM
Cell Res; 2011 Jan; 21(1):22-39. PubMed ID: 21119682
[TBL] [Abstract][Full Text] [Related]
5. The equilibrium of tumor suppression: DUBs as active regulators of PTEN.
Christine A; Park MK; Song SJ; Song MS
Exp Mol Med; 2022 Nov; 54(11):1814-1821. PubMed ID: 36385557
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitinases and the new therapeutic opportunities offered to cancer.
Pfoh R; Lacdao IK; Saridakis V
Endocr Relat Cancer; 2015 Feb; 22(1):T35-54. PubMed ID: 25605410
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin ligases in malignant lymphoma.
Lim MS; Elenitoba-Johnson KS
Leuk Lymphoma; 2004 Jul; 45(7):1329-39. PubMed ID: 15359630
[TBL] [Abstract][Full Text] [Related]
8. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
[TBL] [Abstract][Full Text] [Related]
9. Dissenting degradation: Deubiquitinases in cell cycle and cancer.
Bonacci T; Emanuele MJ
Semin Cancer Biol; 2020 Dec; 67(Pt 2):145-158. PubMed ID: 32201366
[TBL] [Abstract][Full Text] [Related]
10. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
11. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN.
Takiuchi T; Nakagawa T; Tamiya H; Fujita H; Sasaki Y; Saeki Y; Takeda H; Sawasaki T; Buchberger A; Kimura T; Iwai K
Genes Cells; 2014 Mar; 19(3):254-72. PubMed ID: 24461064
[TBL] [Abstract][Full Text] [Related]
12. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
13. The Multifaceted Roles of USP15 in Signal Transduction.
Das T; Song EJ; Kim EE
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946990
[TBL] [Abstract][Full Text] [Related]
14. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors.
Hussain S; Zhang Y; Galardy PJ
Cell Cycle; 2009 Jun; 8(11):1688-97. PubMed ID: 19448430
[TBL] [Abstract][Full Text] [Related]
15. p53 stability is regulated by diverse deubiquitinating enzymes.
Kwon SK; Saindane M; Baek KH
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):404-411. PubMed ID: 28801249
[TBL] [Abstract][Full Text] [Related]
16. Regulation of NF-κB by deubiquitinases.
Harhaj EW; Dixit VM
Immunol Rev; 2012 Mar; 246(1):107-24. PubMed ID: 22435550
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2.
Wang H; Lai Y; Mathis BJ; Wang W; Li S; Qu C; Li B; Shao L; Song H; Janicki JS; Sun SC; Wang XL; Tang D; Cui T
J Mol Cell Cardiol; 2015 Jul; 84():143-53. PubMed ID: 25935309
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
Yoshida H; Jono H; Kai H; Li JD
J Biol Chem; 2005 Dec; 280(49):41111-21. PubMed ID: 16230348
[TBL] [Abstract][Full Text] [Related]
19. Structure and function of the highly homologous deubiquitinases ubiquitin specific peptidase 25 and 28: Insights into their pathophysiological and therapeutic roles.
Zhou L; Qin B; Yassine DM; Luo M; Liu X; Wang F; Wang Y
Biochem Pharmacol; 2023 Jul; 213():115624. PubMed ID: 37245535
[TBL] [Abstract][Full Text] [Related]
20. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
